Clinical Trial Update: First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer [Phase 1]

View source ↗

Summary

This clinical trial update announces the first-in-human, Phase 1 study of ATX-295, an oral inhibitor of KIF18A, in patients with advanced or metastatic solid tu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• High-grade Serous Ovarian Carcinoma
• Ovarian Cancer
• Solid Tumors
• Triple-negative Breast Cancer

Drugs mentioned

• ATX-295

Snippet

Sponsor: Accent Therapeutics | Conditions: Advanced Solid Tumors, Breast Cancer Recurrent | Phase 1 | Status: RECRUITING